Vanda Pharmaceuticals Crecimiento futuro

Future controles de criterios 1/6

Se prevé que los ingresos de Vanda Pharmaceuticals disminuyan a un ritmo anual de 4.3%, mientras que se prevé que sus beneficios anuales crezcan a un ritmo de 2.4% por año. Se espera que el BPA disminuya en un 0.8% al año.

Información clave

2.4%

Tasa de crecimiento de los beneficios

-0.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.7%
Tasa de crecimiento de los ingresos	-4.3%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	27 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

Apr 05

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Feb 15

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Feb 13

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Feb 10

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

Nov 11

One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

May 12

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:VNDA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	152	9	298	299	1
12/31/2025	232	-19	254	255	1
12/31/2024	195	-4	190	191	1
12/31/2023	193	3	-88	13	N/A
9/30/2023	212	12	26	26	N/A
6/30/2023	238	15	40	41	N/A
3/31/2023	257	16	59	60	N/A
12/31/2022	254	6	31	32	N/A
9/30/2022	258	6	49	49	N/A
6/30/2022	263	11	45	46	N/A
3/31/2022	266	18	59	59	N/A
12/31/2021	269	33	64	64	N/A
9/30/2021	268	34	56	57	N/A
6/30/2021	259	32	55	57	N/A
3/31/2021	253	32	60	62	N/A
12/31/2020	248	23	50	52	N/A
9/30/2020	241	19	41	42	N/A
6/30/2020	241	114	38	39	N/A
3/31/2020	237	117	34	35	N/A
12/31/2019	227	116	45	46	N/A
9/30/2019	219	122	50	51	N/A
6/30/2019	209	28	53	54	N/A
3/31/2019	197	22	12	38	N/A
12/31/2018	193	25	5	30	N/A
9/30/2018	184	13	-7	18	N/A
6/30/2018	177	1	-14	12	N/A
3/31/2018	171	-5	4	5	N/A
12/31/2017	165	-16	-4	-2	N/A
9/30/2017	159	-14	N/A	-7	N/A
6/30/2017	156	-10	N/A	-8	N/A
3/31/2017	150	-13	N/A	-9	N/A
12/31/2016	146	-18	N/A	-8	N/A
9/30/2016	140	-32	N/A	-7	N/A
6/30/2016	129	-41	N/A	-13	N/A
3/31/2016	121	-42	N/A	2	N/A
12/31/2015	110	-40	N/A	12	N/A
9/30/2015	93	45	N/A	-1	N/A
6/30/2015	80	53	N/A	-3	N/A
3/31/2015	63	36	N/A	-52	N/A
12/31/2014	50	20	N/A	-82	N/A
9/30/2014	44	-57	N/A	-80	N/A
6/30/2014	37	-61	N/A	-83	N/A
3/31/2014	35	-43	N/A	-54	N/A
12/31/2013	34	-21	N/A	-40	N/A
9/30/2013	33	-20	N/A	-41	N/A
6/30/2013	33	-20	N/A	-41	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (2.4% al año) de VNDA es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (2.4% al año) de VNDA crezcan menos que el mercado US (14.8% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de VNDA crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos de VNDA disminuyan en los próximos 3 años (-4.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de VNDA disminuyan en los próximos 3 años (-4.3% al año).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de VNDA se prevé que sea elevada dentro de 3 años.

Vanda Pharmaceuticals Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall from profit to US$0.06 loss, revenue upgraded

Consensus revenue estimates increase by 27%

Price target increased to US$11.00

Vanda Pharmaceuticals Inc. Revises Financial Guidance for the Year 2022

Consensus EPS estimates increase by 11%

Consensus forecasts updated

Recent updates

Vanda Pharmaceuticals Inc. to Report Q1, 2024 Results on May 08, 2024

Future Pak, Ltd. submits a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP and others for approximately $450 million.

Future Pak, Ltd. submits a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP and others for approximately $450 million.

Consensus EPS estimates fall from profit to US$0.06 loss, revenue upgraded

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

New minor risk - Share price stability

Vanda Pharmaceuticals' Fanapt (Iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder

Insider recently sold US$73k worth of stock

Founder notifies of intention to sell stock

Vanda Pharmaceuticals Announces FDA Update for Supplemental NDA for HETLIOZ in the Treatment of Insomnia

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Consensus revenue estimates increase by 27%

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia

Vanda Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 07, 2024

Vanda Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Approval for VTR-297 for the Treatment of Onychomycosis

Vanda Pharmaceuticals Inc. Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

Now 21% undervalued after recent price drop

Vanda Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis

Now 21% undervalued after recent price drop

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

Third quarter 2023 earnings released: EPS: US$0.002 (vs US$0.058 in 3Q 2022)

Vanda Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 08, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vanda Pharmaceuticals Inc. to Report Q2, 2023 Results on Jul 27, 2023

Senior VP recently sold US$96k worth of stock

Senior VP notifies of intention to sell stock

Vanda Pharmaceuticals Inc Reports Results from a Phase III study of Tradipitant in Motion Sickness

One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

Vanda Pharmaceuticals Inc. Responds to the Ruling in its Hetlioz(R) Abbreviated New Drug Application Appeal

First quarter 2023 earnings released: EPS: US$0.057 (vs US$0.12 loss in 1Q 2022)

Insider recently sold US$105k worth of stock

Founder notifies of intention to sell stock

Insufficient new directors

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Vanda Pharmaceuticals Inc. to Report Q4, 2022 Results on Feb 08, 2023

Vanda Pharmaceuticals Inc. Announces Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study

Senior VP recently sold US$56k worth of stock

Vanda Pharmaceuticals Provides an Update to HETLIOZ ANDA Litigation Appeal: Federal Circuit Grants Motion to Temporarily Enjoin Generic Launch

Now 45% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Founder notifies of intention to sell stock

Vvanda Pharmaceuticals Inc. Reports Results in A Phase II Clinical Study of Vqw-765 in the Treatment of Acute Performance Anxiety

Price target increased to US$11.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Vanda Pharmaceuticals Inc. Revises Financial Guidance for the Year 2022

Vanda Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 02, 2022

Now 20% undervalued after recent price drop

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Vanda Pharmaceuticals Inc. Securities Litigation

Vanda Pharmaceuticals: What The Recent Partnership Entails

Vanda Pharma, OliPass collaborate to develop oligonucleotide-based therapeutics

Vanda Pharmaceuticals Inc. Announces Notice of Opportunity for an FDA Hearing on the sNDA for HETLIOZ in Jet Lag Disorder

Consensus EPS estimates increase by 11%

Senior VP recently sold US$86k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Vanda Pharmaceuticals Inc. Provides Revenue Guidance for the Full Year 2022

Vanda Pharmaceuticals Q2 Earnings Preview

Vanda Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 03, 2022

Lead Independent Director notifies of intention to sell stock

Vanda Pharmaceuticals: Strong Pipeline Developments To Power Long-Term Upside

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Vanda Pharmaceuticals Inc. Provides Financial Guidance for the Year 2022

Price target decreased to US$12.00

Vanda Pharmaceuticals Inc., Annual General Meeting, Jun 16, 2022

Vanda: A Dual Growth And Value Player